1
|
Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Filipponi F, Bartolozzi C, Del Tacca M, Ricci S. A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4592] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4592 Background: S, an oral multi-kinase inhibitor that targets Raf-kinase and receptor tyrosine kinases, improved overall survival (OS) and time to progression (TTP) versus placebo in a randomized phase III study in HCC (SHARP study). The safety of S in association with infusional and bolus 5FU regimens was established in a previous PhI study, with no clinically relevant pharmacokinetic interaction between S and 5FU. The present trial was designed to evaluate the safety and efficacy of S with infusional 5FU in HCC pts. Methods: Patients with advanced HCC (not eligible to surgical or locoregional therapies), age≥18 years, Child-Pugh Class A or B, ECOG PS 0–1, without prior systemic treatment for HCC and adequate bone marrow, liver and renal function, were eligible for the study. The primary endpoint is the Disease Control Rate (DCR). Secondary endpoints included response rate, TTP, OS and safety. According to a two-step Simon's model 46 pts were to be accrued. Pts were treated with oral S 400 mg bid continuously and c.i. 5FU 200 mg/sqm/day day 1–14 every 3 weeks. Tumour response was assessed according to RECIST criteria every 9 weeks. Results: Between October 2006 and October 2008 38 pts were enrolled: M-F: 32–6, median age (range): 68(47–83) years, ECOG-PS 0–1: 28–10, Child-Pugh A-B: 35–3, extrahepatic spread: 14 pts, macroscopic vascular invasion: 6 pts. Grade 3/4 (%) toxicities (NCI CTC v 3.0 criteria) included diarrhoea 5/0, stomatitis 21/3, hand foot syndrome 21/0, skin rash 11/0, hypertension 11/0; hyperbilirubinemia 5/3, AST 11/0, ALT 8/0, cardiac toxicity (one cardiac failure, one atrial fibrillation) 5/0 and bleeding (melena) in 3/0. One partial response was observed. Stable disease was obtained in 45% of pts with a median duration of 9.6 months (range 5–18+). Median TTP was 7.6 months (CI 95%=5.3–9.9) and median OS 12.2 months (CI 95%=4.45–19.8). Conclusions: Preliminary results of this PhII study show encouraging disease control rate, TTP and OS in pts with advanced HCC. The S+5FU association is feasible, well tolerated and AEs were predictable and manageable. [Table: see text]
Collapse
Affiliation(s)
- I. Petrini
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - M. Lencioni
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - M. Ricasoli
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - M. Iannopollo
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - C. Orlandini
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - F. Oliveri
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - F. Filipponi
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - C. Bartolozzi
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - M. Del Tacca
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| | - S. Ricci
- Università degli Studi di Pisa, Pisa, Italy; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Università di Pisa, Pisa, Italy
| |
Collapse
|
2
|
Tibaldi C, Ricci S, Russo F, Chioni A, Iannopollo M, Galli L, Grosso A, Lopes Pegna A, Puccinelli P, Fabbri A. Chemotherapy with gemcitabine in elderly patients (or in patients not candidate for a cisplatin regimen) with advanced NSCLC: a multicenter phase II study. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80700-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
Sarica G, Iannopollo M, Martelli G, Multari E, Grenci G, Sirleo E. [Hypertrophy and left ventricular function following angiotensin-converting enzyme inhibition in hypertensive patients. Echocardiographic analysis]. Minerva Cardioangiol 1987; 35:621-9. [PMID: 2965319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|